| 1. |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent. 2024 Feb 2;4(1): 47-53.
|
| 2. |
Global cancer burden growing, amidst mounting need for services[J]. Saudi Med J, 2024, 45(3): 326-327.
|
| 3. |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
|
| 4. |
Passaro A, Attili I, de Marinis F. Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2022, 40(25): 2871-2877.
|
| 5. |
Gao J, Zhang H, Zhang F. Research progress of TIPE2 in immune-related diseases[J]. Int Immunopharmacol, 2023, 121: 110514.
|
| 6. |
Li A, Chen Y, Zhao X, et al. Characterization and transcriptional regulation analysis of the porcine TNFAIP8L2 gene[J]. Mol Genet Genomics, 2010, 284(3): 185-195.
|
| 7. |
Padmavathi G, Banik K, Monisha J, et al. Novel tumor necrosis factor-alpha induced protein eight (TNFAIP8/TIPE) family: Functions and downstream targets involved in cancer progression[J]. Cancer Lett, 2018, 432: 260-271.
|
| 8. |
Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer[J]. Nat Rev Clin Oncol, 2021, 18(9): 547-557.
|
| 9. |
中華醫學會腫瘤學分會. 中華醫學會肺癌臨床診療指南(2023版)[J]. 中華腫瘤雜志, 2023, 45(7): 539-574.
|
| 10. |
Li T, Wang W, Gong S, et al. Genome-wide analysis reveals TNFAIP8L2 as an immune checkpoint regulator of inflammation and metabolism[J]. Mol Immunol, 2018, 99: 154-162.
|
| 11. |
Li W, Li Y, Guan Y, et al. TNFAIP8L2/TIPE2 impairs autolysosome reformation via modulating the RAC1-MTORC1 axis[J]. Autophagy, 2021, 17(6): 1410-1425.
|
| 12. |
Lou Y, Song M, Han M, et al. Tumor Necrosis Factor-alpha-Induced Protein 8-Like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer[J]. Cancer Immunol Res, 2022, 10(3): 354-367.
|
| 13. |
Zhu Y, Tao M, Wu J, et al. Adenovirus-directed expression of TIPE2 suppresses gastric cancer growth via induction of apoptosis and inhibition of AKT and ERK1/2 signaling[J]. Cancer Gene Ther, 2016, 23(4): 98-106.
|
| 14. |
Zhao Q, Zhao M, Dong T, et al. Tumor necrosis factor-alpha-induced protein-8 like-2 (TIPE2) upregulates p27 to decrease gastic cancer cell proliferation[J]. J Cell Biochem, 2015, 116(6): 1121-1129.
|
| 15. |
Tang Z, Zhang D, Yao C, et al. TIPE2 inhibits the migration and invasion of epithelial ovarian cancer cells by targeting Smad2 to reverse TGF-beta1-induced EMT[J]. FASEB J, 2024, 38(17): e70045.
|
| 16. |
Li Y, Li X, Liu G, et al. Downregulated TIPE2 is associated with poor prognosis and promotes cell proliferation in non-small cell lung cancer[J]. Biochem Biophys Res Commun, 2015, 457(1): 43-49 .
|
| 17. |
樊朝昕, 傅瀟, 姚煜. EGFR突變晚期非小細胞肺癌免疫治療的研究進展[J]. 現代腫瘤醫學, 2022, 30(11): 2069-2073.
|
| 18. |
Wang Y, Safi M, Hirsch FR, et al. Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions[J]. Nat Rev Clin Oncol, 2025, 22(3): 200-214.
|
| 19. |
王琰, 盧斌峰, 蔣敬庭. 腫瘤浸潤淋巴細胞及其亞群在腫瘤免疫中的作用[J]. 臨床檢驗雜志, 2018, 36(11): 854-857.
|
| 20. |
Lv T, Fan R, Wu J, et al. Tumor-Associated Macrophages: Key Players in the Non-Small Cell Lung Cancer Tumor Microenvironment[J]. Cancer Med, 2025, 14(3): e70670.
|
| 21. |
曾瑞紅, 房桂珍, 魏林. CD4+T 細胞在腫瘤免疫治療中的作用[J]. 細胞生物學雜志2008, 30(1): 30-34.
|
| 22. |
Belabed M, Park MD, Blouin CM, et al. Cholesterol mobilization regulates dendritic cell maturation and the immunogenic response to cancer[J]. Nat Immunol, 2025, 26(2): 188-199.
|